Investor Relations

Welcome to our dedicated page for investor resources. You will find everything you need if you want to invest in pioneering medical science.

Dedicated to solving some of today’s biggest public health challenges, bioMérieux has the focus and the capabilities to discover, develop, and commercialize advanced medical diagnostics solutions that have an impact on people’s lives. We combine the dynamism of a technology-fueled company with the long-term thinking of our founding family. It is this alliance that shapes our strategy and success.

A values-based company, we aim for strong and sustainable performance that benefits our shareholders, our employees, and society.

Investors

2022 Financial Results

Strong sales growth in the fourth quarter:
- Organic growth of 5.9%
- Very high demand for respiratory panels within the “tripledemic” (Flu/Covid/RSV) context
- Remarkable growth in non-respiratory panels and Industrial Applications
Strong performance in 2022 with robust full-year sales and 18.5% contributive operating margin, above initial expectations
Confirmed 2023 guidance

“In 2022, bioMérieux achieved a solid performance and adjusted upward its guidance during the year. The year has been marked by the acquisition of Specific Diagnostics which reinforces our product offering and our long-standing commitment to the fight against antimicrobial resistance. 2022 has been also an intense year in R&D and launch of several new platforms that will contribute to strengthen our market positions and sustain our growth”

Alexandre Mérieux, Chairman and CEO